Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR Gene Therapy in Metastatic Melanoma
NCT02654821Phase 2Unknown
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2012
- Primary completion
- Oct 2019
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KITE-718 in melanoma, sponsored by Netherlands Cancer Institute. Primary endpoints: Safety of the TCR treatment (according to CTCAE 4.0) at 4 weeks and Objective response rate according to RECIST 1.1 at 6 months. Status: unknown.
02
Drugs
KITE-718
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02654821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02654821.